The landscape of oligonucleotide-based treatments, such as guide RNAs and siRNAs, is evolving towards increased complexity. This complexity poses significant challenges in effectively separating the desired products from impurities, impacting the purity, safety, and regulatory compliance of these therapeutics. Traditional purification methods like strong anion exchange (AX) and ion-pair reversed-phase (IPRP) chromatography are vital in purifying synthetic oligos. However, as the sequences become more closely related, especially with the rise in length and chemical intricacy, novel approaches are required to ensure efficient separation.
In a recent GEN webinar, Dr. Joe Guiles presented an innovative two-step purification process for oligonucleotides utilizing strong anion exchange combined with ion-pair reversed-phase (AX-IPRP) chromatography. This method aims to achieve high-resolution separation of impurities without the need for chemical modifications or specialized equipment. It is versatile, catering to a wide range of oligo sequences and ligand chemistries. Key highlights of this webinar include addressing:
- The structural complexities posed by the length and chemical diversity of oligonucleotides, impacting purification outcomes and regulatory adherence.
- The effectiveness of the AX-IPRP workflow in attaining over 80% purity for lengthy guide RNAs, such as 100-mers, with excellent step recovery rates and minimal process intricacies.
- Practical considerations for seamlessly integrating these purification techniques into existing manufacturing setups, encompassing aspects like resin selection, controlling residual buffers, and implementing robust process control strategies.
The webinar also featured an interactive Q&A session, providing attendees with the opportunity to engage with the expert panelist and delve deeper into the subject matter. As the field of nucleic acid therapeutics progresses, optimizing purification strategies is crucial to ensure the efficacy and safety of these innovative treatments.
Furthermore, the constantly evolving nature of oligonucleotide-based therapeutics demands advanced purification techniques that can effectively handle the increasing complexity of these molecules. By leveraging cutting-edge approaches like the AX-IPRP chromatography, researchers and manufacturers can enhance the purification process, ensuring the production of high-quality oligonucleotide therapeutics that meet stringent regulatory standards.
Takeaways:
– The importance of innovative purification strategies in overcoming the challenges posed by the complexity of oligonucleotide-based therapeutics.
– The impact of the AX-IPRP chromatography method in achieving high purity levels for intricate oligo sequences.
– Practical insights into integrating advanced purification techniques into existing manufacturing processes for nucleic acid therapeutics.
Tags: regulatory, mass spectrometry, chromatography
Read more on genengnews.com